Venus concept submits fda 510(k) related to the use of its aime™ next generation robotic technology for tissue excision and skin resurfacing

Toronto, march 31, 2022 (globe newswire) -- venus concept inc. (“venus concept” or the “company”) (nasdaq: vero), a global medical aesthetic technology leader, today announced it has submitted a 510(k) premarket notification (“510(k)”) to the u.s. food and drug administration ("fda"), which is intended to obtain a general clinical indication related to the use of its aime™ next generation robotic technology for tissue excision and skin resurfacing. aime is a robotic platform designed to provide micro-coring for medical aesthetic applications.
VERO Ratings Summary
VERO Quant Ranking